Investigating iLux Efficacy in Contact Lens Wearers With Evaporative Dry Eye Disease (SHEEPDOG)

The purpose of this clinical trial is to investigate the efficacy of a single iLux® treatment in symptomatic CL wearers who have DED (according to the TFOS DEWS II diagnostic criteria), of the evaporative dry eye disease subtype (EDE).

Study Overview

• Status: Terminated
• Conditions: Dry Eye
• Intervention / Treatment: Device: iLux® system

• Study Type: Interventional
• Enrollment (Actual): 28
• Phase: Phase 4

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Waterloo, Ontario, Canada, N2L 3G1
      • Centre for Ocular Research & Education

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Is at least 18 years of age and has full legal capacity to volunteer;
2. Has read and signed an information consent letter;
3. Is willing and able to follow instructions and maintain the appointment schedule;
4. Has been using the same CL type (brand, material and dimensions) for > 3 months;
5. Wears commercially available soft CLs on average >2 hours per day, 4-7 days per week;
6. Is willing to try to wear their habitual CLs on average ≥ 6 hours per day, 4-7 days per week and maintain this for the duration of their involvement in the study;
7. Demonstrates an acceptable lens fit of their habitual contact lenses;
8. Does not have contact lens discomfort due to contact lens fit, lens material or known solution compatibility issues, in the opinion of the investigator;
9. Has at least one month supply of their habitual contact lens products at the time of the screening visit;
10. Has a CLDEQ-8 score ≥ 12;

11. Has dry eye symptoms without CL wear (OSDI ≥ 13) and has at least one of the two following signs:

    1. Non-invasive tear break-up time (NITBUT) of < 10 seconds in at least one eye;
    2. Fluorescein staining: > 5 spots of corneal staining OR > 9 conjunctival spots OR lid wiper staining (≥ 2mm length, ≥ 25% width) in at least one eye;
12. Has a lipid layer thickness of ≤ 100 nm in both eyes;
13. A meibomian gland secretion score (MGS) of ≤ 15 for 15 glands of the lower lid in both eyes.

Exclusion Criteria:

1. Is participating in any concurrent clinical or research study;
2. Has used any prescription systemic medications or topical treatments for MGD or dry eye for the past 30 days prior to the screening visit and not willing to stop using these for the study duration (excluding over-the-counter artificial tears, dietary supplements and ocular lubricants but includes warm compresses, eyelid massage, eyelid hygiene, manual meibomian gland expression, punctal plug insertion or punctal occlusion, intense pulsed light treatment of the face or eyelids);
3. Has previously received treatment with an eyelid thermal pulsation device;

4. Has a history of any of the following ocular (eye or eyelid) conditions or procedures in either eye within the past 90 days prior to the screening visit:

   1. Ocular trauma
   2. Chemical burns
   3. Ocular Herpes simplex or Herpes zoster infection
   4. Limbal stem cell deficiency
   5. Recurrent ocular inflammation (e.g. uveitis, iritis, scleritis, episcleritis, keratitis)
5. Has undergone ocular surgery (e.g. intraocular, oculoplastic, corneal or refractive surgery procedure) within the past 12 months prior to the screening visit;
6. Has permanent make-up or tattoos on their eyelids;
7. Has any other known active* ocular disease and/or infection in either eye including: cicatricial lid margin disease or severe (≥ grade 3) blepharitis; moderate to severe (grade 2-4) allergic, vernal or giant papillary conjunctivitis; a hordeolum or stye; ocular surface abnormality that may compromise corneal integrity (e.g. Grade 3 corneal fluorescein staining, recurrent corneal erosion, corneal epithelial defect, map dot fingerprint dystrophy, previously treated chemical burn);
8. Has an eyelid abnormality that affects normal lid function (e.g. entropion, ectropion, oedema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis);
9. Has a systemic condition that in the opinion of the investigator may affect a study outcome variable;
10. Has any other condition that could compromise treatment or increase the risk of a procedure-related injury;
11. Is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable;
12. Has known sensitivity to the diagnostic pharmaceuticals to be used in the study;
13. Has a history of sensitivity to rapidly blinking lights or photosensitive epilepsy;
14. Is pregnant, lactating or planning a pregnancy (by verbal communication) at the time of enrolment;
15. Is aphakic;
16. Is a member of CORE directly involved in the study;
17. Has taken part in a clinical research study within the last 30 days. * For the purposes of this study, active ocular disease is defined as infection or inflammation which requires therapeutic treatment. Mild (i.e. not considered clinically relevant) lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and dry eye are not considered active ocular disease. Neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: iLux® treatment; The treatment group will receive iLux® treatment at Visit 1 and will be reviewed 1- and 3-months after iLux® treatment.	Device: iLux® system; Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
Experimental: Delayed iLux® treatment; Delayed iLux® treatment provided after 1 month (i.e. 1 month of no treatment, administer treatment after 1 month). Review 1- and 3-months after iLux® treatment.	Device: iLux® system; Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Change in the Standard Patient Evaluation of Eye Dryness (SPEED) Questionnaire Score From Baseline to 1 Month	The mean change in dry eye symptoms from baseline based on the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire score was evaluated 1 month after iLux treatment. The SPEED questionnaire is a dry eye questionnaire developed to assess the frequency (0-3 scale, with higher values indicating more frequent symptoms) and severity (0-4 scale, with higher values indicating more severe symptoms) of patient symptoms. Scores range from 0-28. A higher SPEED score represents more frequent and/or more severe symptoms.	1 month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Meibomian Gland Score at Baseline	To determine the meibomian gland score, secretion characteristics of 15 meibomian glands along the lower eyelid were evaluated including five glands each in the temporal, central and nasal regions of the lower eyelid. For each gland, secretion characteristics were graded as 3 (clear liquid), 2 (cloudy liquid), 1 (inspissated/ toothpaste consistency) and 0 (no secretion). The total meibomian gland score is the sum of the grades for all 15 glands with a range between 0 and 45. A higher score reflects less meibomian gland dysfunction.	Baseline
Meibomian Gland Score at 1 Month	To determine the meibomian gland score, secretion characteristics of 15 meibomian glands along the lower eyelid were evaluated including five glands each in the temporal, central and nasal regions of the lower eyelid. For each gland, secretion characteristics were graded as 3 (clear liquid), 2 (cloudy liquid), 1 (inspissated/ toothpaste consistency) and 0 (no secretion). The total meibomian gland score is the sum of the grades for all 15 glands with a range between 0 and 45. A higher score reflects less meibomian gland dysfunction.	1 Month
Meibomian Gland Score at 3 Months	To determine the meibomian gland score, secretion characteristics of 15 meibomian glands along the lower eyelid were evaluated including five glands each in the temporal, central and nasal regions of the lower eyelid. For each gland, secretion characteristics were graded as 3 (clear liquid), 2 (cloudy liquid), 1 (inspissated/ toothpaste consistency) and 0 (no secretion). The total meibomian gland score is the sum of the grades for all 15 glands with a range between 0 and 45. A higher score reflects less meibomian gland dysfunction.	3 Months
Pre-lens Tear Break-up Time at Baseline	The pre-lens tear film is the layer of tears located on top of the contact lens (i.e., between the eye lid and the contact lens). The time required for a dry spot to appear on the contact lens surface after blinking is referred to as the pre-lens tear break-up time. Three measurements are taken and averaged together. A higher number represents a longer pre-lens tear break-up time.	Baseline
Pre-lens Tear Break-up Time at 1 Month	The pre-lens tear film is the layer of tears located on top of the contact lens (i.e., between the eye lid and the contact lens). The time required for a dry spot to appear on the contact lens surface after blinking is referred to as the pre-lens tear break-up time. Three measurements are taken and averaged together. A higher number represents a longer pre-lens tear break-up time.	1 Month
Pre-lens Tear Break-up Time at 3 Months	The pre-lens tear film is the layer of tears located on top of the contact lens (i.e., between the eye lid and the contact lens). The time required for a dry spot to appear on the contact lens surface after blinking is referred to as the pre-lens tear break-up time. Three measurements are taken and averaged together. A higher number represents a longer pre-lens tear break-up time.	3 Months
Comfortable Contact Lens Wear Time at Baseline	Participants reported how long the contact lenses on average were comfortable (comfortable wear time).	Baseline
Comfortable Contact Lens Wear Time at 1 Month	Participants reported how long the contact lenses on average were comfortable (comfortable wear time).	1 Month
Comfortable Contact Lens Wear Time at 3 Months	Participants reported how long the contact lenses on average were comfortable (comfortable wear time).	3 Months
Average Contact Lens Wear Time at Baseline	Participants reported how long they wore their contact lenses on average per day (total wear time).	Baseline
Average Contact Lens Wear Time at 1 Month	Participants reported how long they wore their contact lenses on average per day (total wear time).	1 Month
Average Contact Lens Wear Time at 3 Months	Participants reported how long they wore their contact lenses on average per day (total wear time).	3 Months

Collaborators and Investigators

• Sponsor: University of Waterloo
• Collaborators: Alcon Research
• Investigators: Principal Investigator: Lyndon Jones, PhD, FCOptom, Centre for Ocular Research & Education

Study record dates

Study Major Dates

• Study Start (Actual): November 15, 2019
• Primary Completion (Actual): April 14, 2020
• Study Completion (Actual): April 14, 2020

Study Registration Dates

• First Submitted: November 7, 2019
• First Submitted That Met QC Criteria: November 8, 2019
• First Posted (Actual): November 12, 2019

Study Record Updates

• Last Update Posted (Actual): May 16, 2023
• Last Update Submitted That Met QC Criteria: May 12, 2023
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Lacrimal Apparatus Diseases; Keratoconjunctivitis; Conjunctivitis; Conjunctival Diseases; Keratitis; Corneal Diseases; Eye Diseases; Dry Eye Syndromes; Keratoconjunctivitis Sicca
• Other Study ID Numbers: 41401

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes